ReviewCancer cell international2026
Natural compounds in the treatment of osteosarcoma: just chemotherapy adjuvants? or is there much more?
Review in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A 'three-axis synergy' immunotherapeutic strategy for malignant bone tumors based on natural bioactives and bioactive materials.Bioactive materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common type of bone tumor. Different therapeutic approaches are used in the management of osteosarcoma, where surgery is most often performed, often preceded and followed by chemotherapy, which however has serious short- and long-term side effects. Recently, much attention has been paid to natural compounds that can determine cell death of tumor. Some have a direct cytotoxic effect, and they also can reduce tumor and metastatic activity. Furthermore, it described how these molecules can also interact with elective chemotherapy against osteosarcoma. In this review, we have analysed the last decade literature, highlighting both the studies that have a direct cytotoxic effect on osteosarcoma, and those that are used as adjuvants to chemotherapy, allowing to reduce treatment doses, limiting the side effects. The comparison between the different studies have led to relevant considerations on the study standardization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.